NervGen Pharma Corp. Financials
NGEN
All currency values in C$ millions unless otherwise noted
| Income Statement | TTM | DEC 2025 | DEC 2024 |
|---|---|---|---|
| Revenues | |||
| Revenue | C$0 | C$0 | C$0 |
| Operating Income | -C$32 | -C$25 | -C$25 |
| Net Income | |||
| Net Income | -C$62 | -C$44 | -C$24 |
| Per Share Data | |||
| Revenue Per Share | C$0.00 | – | – |
| EPS (Basic) | -C$0.67 | – | – |
| EPS (Diluted) | -C$0.67 | – | – |
| Shares Outstanding | 92.4M | – | – |
NervGen Pharma (NGEN) financials: revenue, profit and margins
NervGen Pharma (NGEN) generated about C$0.00 in revenue and -C$62 million in net income over the trailing twelve months. Figures are from company filings; this is analysis, not investment advice.
Frequently asked
What is NervGen Pharma's (NGEN) revenue?+
NervGen Pharma generated about C$0.00 in revenue over the trailing twelve months. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Is NervGen Pharma profitable?+
NervGen Pharma reported about -C$62 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
Peers
Biotechnology · Pick stocks to compare with NGEN
Held by ETFs
NGEN is in 1 US ETF. The largest of them, with NGEN's weight in each:
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing NGEN
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.